Table 3

 Analysis for last drug observation carried forward

VariableCombination (n = 56)SASP (n = 55)MTX (n = 54)Comb v SASP*p ValueComb v MTX*p ValueSASP v MTX*p Value
CRP, C reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MTX, methotrexate; SASP, sulfasalazine.
A positive value indicates an increase in the variable over the trial period. Data are median (IQR) increase in score. Changes are 18-month values minus 6-month values.
*Mann–Whitney U test used.
DAS–0.67 (–1.38 to –0.21)–0.3 (–0.8 to 0)–0.26 (–0.99 to 0)0.0390.0230.79
HAQ–0.5 (–10.25 to 0.06)–0.25 (–9.13 to 0.13)–0.19 (–10.25 to 0.13)0.510.570.99
Ritchie articular index–4 (–7.5 to –0.5)–3 (–9 to 1)0 (–6 to 3)0.430.0190.13
Swollen joint count–3 (–4 to –0.5)–3 (–6 to 0)–2 (–6 to 0)0.940.810.74
Pain score–8 (–27.5 to 2)0 (–13 to 7)0 (–23 to 11)0.0710.250.58
Patient global–11.5 (–27.5 to 0.5)0 (–15 to 5)–7 (–26 to 2)0.060.720.14
Physician global–12.5 (–25 to 0)–4 (–15 to 5)–5 (–22 to 0)0.0440.620.13
ESR0 (–8.5 to 1)0 (–4 to 9)1 (–3 to 6)0.0870.0330.86
CRP0 (–5.5 to 1)0 (–1 to 2)0 (–3 to 2)0.180.240.90